These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29076829)

  • 1. Comparative effectiveness trials in asthma - how will I recognize one?
    Nyenhuis SM; Apter AJ; Schatz M; Krishnan JA
    Curr Opin Pulm Med; 2018 Jan; 24(1):78-82. PubMed ID: 29076829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
    Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
    Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
    Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
    J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The PRECIS-2 tool: designing trials that are fit for purpose].
    Hu GP; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):222-226. PubMed ID: 29495210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
    Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
    Trials; 2016 Jan; 17():32. PubMed ID: 26772801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pragmatic vs. explanatory: an adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice.
    Koppenaal T; Linmans J; Knottnerus JA; Spigt M
    J Clin Epidemiol; 2011 Oct; 64(10):1095-101. PubMed ID: 21474282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
    Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
    Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do randomized controlled nursing trials have a pragmatic or explanatory attitude? Findings from the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool exercise.
    Palese A; Bevilacqua MG; Dante A;
    J Nurs Res; 2014 Sep; 22(3):216-20. PubMed ID: 25111115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
    Bratton DJ; Nunn AJ; Wojnarowska F; Kirtschig G; Sandell A; Williams HC
    Trials; 2012 Apr; 13():50. PubMed ID: 22540678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of PRECIS-2 ratings in randomized controlled trials of Chinese herbal medicine.
    Lu L; Zhou L; Dong J; Xiang Y; Wen Z
    Oncotarget; 2017 Dec; 8(63):107002-107010. PubMed ID: 29291006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pragmatism in explaining heterogeneity in meta-analyses of randomised trials: a protocol for a cross-sectional methodological review.
    Aves T; Allan KS; Lawson D; Nieuwlaat R; Beyene J; Mbuagbaw L
    BMJ Open; 2017 Sep; 7(9):e017887. PubMed ID: 28871028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing provider-focused implementation trials with purpose and intent: introducing the PRECIS-2-PS tool.
    Norton WE; Loudon K; Chambers DA; Zwarenstein M
    Implement Sci; 2021 Jan; 16(1):7. PubMed ID: 33413489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
    Thorpe KE; Zwarenstein M; Oxman AD; Treweek S; Furberg CD; Altman DG; Tunis S; Bergel E; Harvey I; Magid DJ; Chalkidou K
    J Clin Epidemiol; 2009 May; 62(5):464-75. PubMed ID: 19348971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
    Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
    Trials; 2013 Apr; 14():115. PubMed ID: 23782862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the PRECIS criteria to describe three effectiveness trials of weight loss in obese patients with comorbid conditions.
    Glasgow RE; Gaglio B; Bennett G; Jerome GJ; Yeh HC; Sarwer DB; Appel L; Colditz G; Wadden TA; Wells B
    Health Serv Res; 2012 Jun; 47(3 Pt 1):1051-67. PubMed ID: 22092292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informing real-world practice with real-world evidence: the value of PRECIS-2.
    Neta G; Johnson KE
    BMC Med; 2018 May; 16(1):76. PubMed ID: 29783964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) model in clinical research: Application to refine a practice-based research network (PBRN) study.
    Elder WG; Munk N
    J Am Board Fam Med; 2014; 27(6):846-54. PubMed ID: 25381083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) instrument was useful for refining a randomized trial design: experiences from an investigative team.
    Riddle DL; Johnson RE; Jensen MP; Keefe FJ; Kroenke K; Bair MJ; Ang DC
    J Clin Epidemiol; 2010 Nov; 63(11):1271-5. PubMed ID: 20670911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews.
    Wieland LS; Berman BM; Altman DG; Barth J; Bouter LM; D'Adamo CR; Linde K; Moher D; Mullins CD; Treweek S; Tunis S; van der Windt DA; Zwarenstein M; Witt C
    J Clin Epidemiol; 2017 Apr; 84():95-104. PubMed ID: 28188898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.